Global Force-of-Infection Trends for Human *Taenia solium* Taeniasis/Cysticercosis

Matthew A. Dixon^{1,2,3*}, Peter Winskill², Wendy E. Harrison^{3,†}, Charles Whittaker^{1,2}, Veronika Schmidt^{4,5}, Astrid Carolina Flórez Sánchez⁶, Zulma M. Cucunubá^{1,2,§}, Agnes U. Edia-Asuke⁷, Martin Walker⁸, Maria-Gloria Basáñez^{1,2}

* Corresponding author: m.dixon15@imperial.ac.uk

1 Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease Research (LCNTDR), Faculty of Medicine, School of Public Health, Imperial College London, London W2 1PG, UK

2 MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Faculty of Medicine, School of Public Health, Imperial College London, London W2 1PG, UK

3 SCI Foundation, Edinburgh House, 170 Kennington Lane, London, SE11 5DP

4 Department of Neurology, Center for Global Health, Technical University Munich (TUM), Munich, Germany

5 Centre for Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway

6 Grupo de Parasitología, Instituto Nacional de Salud, Bogotá, Colombia

7 Ahmadu Bello University, 810211, Zaria, Nigeria

8 Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research (LCNTDR), Royal Veterinary College, Hatfield AL9 7TA, UK

§ Present address: Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Infection by *Taenia solium* poses a major burden across endemic countries. The World Health Organization (WHO) 2021–2030 Neglected Tropical Diseases roadmap has proposed that 30% of endemic countries achieve intensified *T. solium* control in hyperendemic areas by 2030. Understanding geographical variation in age-prevalence profiles and force-of-infection (Fol) estimates will inform intervention designs across settings.

Human taeniasis (HTT) and human cysticercosis (HCC) age-prevalence data from 16 studies in Latin America, Africa and Asia were extracted through a systematic review. Catalytic models, incorporating diagnostic performance uncertainty, were fitted to the data using Bayesian methods, to estimate rates of antibody (Ab)-seroconversion, infection acquisition and Ab-seroreversion or infection loss. HCC Fol and Ab-seroreversion rates were also estimated across 23 departments in Colombia from 28,100 individuals.

Across settings, there was extensive variation in all-ages seroprevalence. Evidence for Ab-seroreversion or infection loss was found in most settings for both HTT and HCC and for HCC Ab-seroreversion in Colombia. The average duration until humans became Ab-seropositive/infected decreased as all-age (sero)prevalence increased. There was no clear relationship between the average duration humans remain Ab-seropositive and all-age seroprevalence.

Marked geographical heterogeneity in *T. solium* transmission rates indicate the need for setting-specific intervention strategies to achieve the WHO goals.

Introduction

The zoonotic cestode *Taenia solium* poses a substantial public health and economic challenge. Globally, *T. solium* is ranked as the foodborne parasitic infection contributing the highest number of disability-adjusted life-years (DALYs), an estimated 2.78 million DALYs in 2010 (Havelaar et al., 2015). Control and elimination of *T. solium* requires a One Health approach (Thomas et al., 2019; Braae et al., 2019) due to its complex multi-host life-cycle, involving infection with larval-stage cysticerci in the intermediate pig host (porcine cysticercosis, or PCC), infective stages (eggs) in the environment, and taeniasis (infection with the adult worm) in the definitive human host (human taeniasis, or HTT). When humans ingest *T. solium* eggs, establishment of cysticerci (human cysticercosis, or HCC) in the central nervous system results in neurocysticercosis (NCC). Neurocysticercosis is responsible for the major health burden associated with *T. solium*, causing approximately one third of epilepsy/seizure disorders in endemic settings (Gripper and Welburn, 2017).

Current interventions target PCC through mass treatment of pigs with oxfendazole and their vaccination with TSOL18, and HTT through mass treatment of humans with praziquantel or niclosamide. These control strategies have proven efficacious in field studies (de Coster et al., 2018; Dixon et al., 2021), but to date no large-scale interventions have been rolled out as part of national Neglected Tropical Disease (NTD) programmes, and therefore their impact alone or in combination in different epidemiological settings remains poorly understood and/or modelled (CystiTeam, 2019). The milestones proposed in the new World Health Organization (WHO) NTD 2021–2030 roadmap (World Health Organization, 2020) focus on achieving intensified control in hyperendemic areas of 17 (27%) endemic countries. However, endemicity levels for *T. solium* have not been defined in terms of infection indicators and there exist limited data on the geographical distribution of *T. solium* prevalence at national scales. For other NTDs, pre-intervention levels of endemicity (according to infection prevalence, intensity, incidence or morbi-mortality) determine the

magnitude, duration and likely success of control efforts (NTD Modelling Consortium Onchocerciasis Group, 2019). Therefore, successful *T. solium* intervention strategies will require tailoring to local epidemiological and socio-economic conditions that determine the intensity of transmission and will likely be informed by age- and/or sex-dependent contact rates and mixing patterns in endemic settings (Dixon et al., 2021; CystiTeam, 2019, Welburn et al., 2015).

Global patterns in transmission rates have recently been explored for PCC by assessing the force-of-infection (Fol; the per-capita rate of infection acquisition) according to proposed endemicity levels (overall (sero)prevalence) and geography (Dixon et al., 2020). Estimates of antibody (Ab) and antigen (Ag) seroconversion (and seroreversion rates) for HCC have also been estimated from a small number of longitudinal surveys in Burkina Faso (Dermauw et al., 2018), Peru (Garcia et al., 2001)], Ecuador (Coral-Almeida et al., 2014) and Zambia (Mwape et al., 2013), demonstrating substantial geographic variation.

Age-prevalence profiles are not only useful for estimating Fol and (sero)reversion rates, but also to provide insight into processes driving epidemiological dynamics, such as immunological responses or heterogeneity in exposure which may explain abrupt changes in HCC seropositivity in older individuals or distinct prevalence peaks in younger ages for HTT prevalence, as observed in the Democratic Republic of the Congo (DRC) (Kanobana et al., 2011; Madinga et al., 2017). Specific age-prevalence profiles may also provide insight into whether age-targeted interventions may be appropriate in certain settings. This study, therefore, and for the first time systematically collates and reviews all HTT and HCC age-(sero)prevalence data available from the literature and from collaborators, and uses simple and reversible catalytic models to estimate the Fol and Ab-seroreversion/infection loss rates from cross-sectional surveys. The results improve our understanding of global variation in the epidemiology of *T. solium* and provide estimates of transmission rates, crucial for guiding the design of interventions. In addition, a country profile of

Fol estimates is presented at the sub-national level for Colombia to exemplify how detailed Fol analyses can help understand local epidemiological patterns.

Results

Systematic review and study selection

After title, abstract and full-text eligibility screening of 236 studies initially identified (01/11/2014 to 02/10/2019), and 11 studies included in the Coral-Almeida et al. (2015) literature review, a total of 16 studies were included in the analysis (PRISMA flowchart; Supplementary File 1: Supplementary Figure S1), originating from South America ($n = 4$), Africa ($n = 8$) and Asia ($n = 4$) (Supplementary File 1: Supplementary Figure S2) and split by $n = 4$ HTT and $n = 15$ HCC surveys (full details in Supplementary File 1: Supplementary Table S1). Total sample sizes were 6,653 individuals (range 576–4,599; with individual age range of <1 to 96 years) across HTT surveys, which included three copro-Ag-based surveys and one Ab-based survey; 34,124 (125–29,360; cross-study age range of <1 to 95 years) across HCC-Ab surveys, and 12,934 (905–4,993; cross-study age range of <1 to 96 years) across HCC-Ag surveys. Observed (sero)prevalence ranged from 4.5% to 23.4% (95% confidence interval (CI) range: 3.0%–24.6%) for HTT surveys, 0.5%–38.7% (0.1%–41.6%) across HCC-Ab surveys, and 0.7%–21.7% (0.5%–24.5%) across HCC-Ag surveys.

Catalytic models (Figure 1; full details in Material and methods) were fitted to the thus extracted (sero)prevalence data using a Bayesian framework that integrates uncertainty in diagnostic sensitivity and specificity from prior (published) information (Supplementary File 1: Supplementary Table S1). The Fol parameters of acquisition (λ) and reversion/loss (ρ) (for antibody datasets: λ_{sero} and ρ_{sero} ; for antigen datasets: λ_{inf} and ρ_{inf}) were estimated for each dataset. The deviance information criterion (DIC) (Spiegelhalter et al., 2002) was used to compare individually- and jointly-fitted catalytic models.

We defined hyperendemic transmission settings as those with all-age *observed* HTT (sero)prevalence of $\geq 3\%$ and all-age *observed* HCC (sero)prevalence of $\geq 6\%$. Studies with (sero)prevalence values below these were defined as endemic transmission settings. These putative endemicity definitions were defined following a literature review of studies referring to “hyper” or “highly” endemic settings (Supplementary File 1: Supplementary Table S2).

[Figure 1 here]

Figure 1. Simple and reversible catalytic model structure and equations fitted to data on the age (a)-specific (sero)prevalence ($p(a)$) data, where λ is the force-of-infection (rate of antibody (Ab)-seroconversion or infection acquisition) and ρ the rate of Ab-seroreversion or infection loss. The general mathematical form of the catalytic models (equations 1a to 1d) fitted to the human taeniasis (HTT)/human cysticercosis (HCC) Ab, HCC Ag and HTT copro-Ag prevalence datasets to estimate the prevalence (p) at human age (a). The saturating (sero)prevalence is given by $\lambda/(\lambda + \rho)$ which for the simple model is 100%, if the humans lived sufficiently long. The accompanying tables provide information on the definitions of the catalytic model parameters depending on the diagnostic method. Presence of adult tapeworm excretory-secretory products indicative of active or past HTT infection, as outlined by Lightowlers et al. 2016a.

Global human taeniasis (HTT) copro-antigen and antibody seroprevalence

Table 1 compares models fitted either including (reversible model) or excluding (simple model) HTT infection loss (when fitted to copro-Ag ELISA using the Allan et al. (1990) protocol datasets, except in Gomes et al. (2002) where a protocol is not specified) or Ab-seroreversion. For the copro-Ag ELISA datasets (to which models were jointly fitted to yield a single sensitivity and specificity posterior), DIC scores were similar (within one unit) between models with and without infection loss (Table 1 and Figure 2a), indicating limited information to differentiate between model fits.

The copro-Ag ELISA datasets (Gomes et al., 2002; Mwape et al., 2012) were found in hyperendemic settings (all-age HTT (sero)prevalence $\geq 3\%$) in Zambia (6.3%) (Mwape et al., 2012) and Brazil (4.5%) (Gomes et al., 2002). For the models independently fitted to the single dataset in Lao People's Democratic Republic (Lao PDR) (Holt et al., 2016) using the rES33-immunoblot (Wilkin et al., 1999) and found in an endemic setting (all-age HTT antibody seroprevalence of 2.5%), there was also limited information to differentiate between model fits, with DIC scores similar (within one unit) between the model with and without Ab-seroconversion (Table 1 and Figure 2b). The FoI (λ_{sero}) for the best-fit model to the rES33-immunoblot antibody dataset in Lao PDR (Holt et al., 2016), suggested a very low HTT Ab-seroconversion rate of 0.00046 year⁻¹ (all model fits and DIC scores in Supplementary File 1: Supplementary File Table S3). The Madinga et al. (2017) dataset in the DRC was omitted from the models jointly fitted across copro-Ag ELISA datasets, due to difficulty fitting catalytic models to such a distinct age-prevalence profile with a marked peak in early ages (see Discussion).

[Figure 2 here]

Figure 2. The relationship between human taeniasis copro-antigen (Copro-Ag) and antibody (sero)prevalence and human age (in years) for each dataset. Human taeniasis (HTT) infection acquisition (simple) or acquisition with infection loss (reversible) catalytic models jointly fitted to multiple datasets (where single diagnostic sensitivity and specificity values were estimated; dataset-specific λ and ρ estimates were obtained) in **a**); HTT antibody (Ab)-seroconversion (simple) or Ab-seroconversion with Ab-seroreversion to a single dataset in **b**). 95% confidence intervals associated with observed (sero)prevalence point estimates are also presented. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the parameter posterior distributions used to construct predicted (all age) (sero)prevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-fitting model selected by deviance information criterion (DIC); both models presented if difference between DIC < 2 (both models have similar support based on the data); a

167 difference > 10 units indicates that the models are significantly different and therefore only superior
 168 fitting model (lowest DIC) is presented). The non-zero predicted (sero)prevalence at age 0 is due to
 169 less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-(sero)prevalence
 170 data-points are calculated by the Clopper-Pearson exact method.

Table 1. (Sero)prevalence and parameter posterior estimates for the best-fit catalytic models fitted to human taeniasis (antibody and antigen) age-(sero)prevalence datasets (ordered by decreasing all-age (sero)prevalence).

Dataset	All-age observed (sero)- prevalence (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	λ = infection acquisition (λ_{inf}) or Ab- seroconversio n (λ_{sero}) rate, year ⁻¹ (95% BCI)**	ρ = infection loss (ρ_{inf}) or Ab- seroreversion (ρ_{sero}) rate, year ⁻¹ (95% BCI)**
Models jointly fitted to multiple datasets (Copro-Ag ELISA) ^a						
Mwape et al. 2012 Antigen [†]	6.32 (4.65 – 8.37)	Reversible ^b	0.824 (0.533 – 0.972)	0.959 (0.941 – 0.976)	0.021 (0.0038 – 0.062)	0.768 (0.362 – 0.991)
Gomes et al. 2002 Antigen ^{††}	4.51 (2.97 – 6.54)				0.0096 (0.00072 – 0.032)	0.731 (0.379 – 0.978)
Models independently fitted to single datasets (rES33-immunoblot) ^c						
Holt et al. 2016 Antibody	2.49 (1.51 – 3.87)	Simple ^d	0.982 (0.959 – 0.996)	0.992 (0.978 – 0.999)	0.00044 (0.000103 – 0.00082)	NA

*Observed (sero)prevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

**Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).

† Based on the Allan et al. (1990) protocol.

†† no protocol specified (assumed to be the Allan et al. (1990) protocol).

NA = Not applicable.

^aDiagnostic sensitivity and specificity jointly fitted for the Copro-Ag ELISA (Allan et al., 1990) across age-prevalence datasets; model parameters interpreted in terms of representing infection, with infection acquisition (λ_{inf}) and infection loss (ρ_{inf}) rates.

^bBest-fitting model determined by DIC (models jointly fitted to multiple dataset).

^cModel parameters for antibody-based age-seroprevalence data (based on the rES33-immunoblot (Wilkins et al., 1999)), interpreted in terms of exposure, with Ab-seroconversion (λ_{sero}) and Ab-seroreversion (ρ_{sero}) rates.

^dBest-fitting model determined by DIC (models independently fitted to single dataset).

171

172

173 **Global human cysticercosis (HCC) antibody seroprevalence**

174 HCC Ab-seroconversion with Ab-seroreversion (reversible model) provided an improved joint fit to
175 the multiple datasets based on the antibody lentil lectin-purified glycoprotein enzyme-linked
176 immunoelectrotransfer blot (LLGP-EITB) assay (Tsang et al., 1989) (Table 2 and Figure 3a). These
177 fits were found in the proposed hyperendemic settings ($\geq 6\%$ HCC seroprevalence; with all-age
178 seroprevalence from 12.7% to 24.7%) in Peru (Lescano et al., 2009; Moro et al., 2003), India
179 (Jayaraman et al., 2011), and Bali (Theis et al., 1994), and an endemic setting in Brazil (1.6%)
180 (Gomes et al., 2002). For the models jointly fitted to multiple datasets based on the IgG Ab-ELISA
181 (*DiagAutom*, 2016) hyperendemic setting: all-age seroprevalence from 9.6% to 14.5%) in Nigeria
182 (Edia-Asuke et al., 2015; Weka et al., 2013), and the models independently fitted to the single
183 dataset from Lao PDR (endemic setting: 3.0% all-age seroprevalence) (Holt et al., 2016) based on
184 the rT24H-immunoblot (Hancock et al., 2006), the (simple) model without Ab-seroreversion
185 provided an improved fit (Table 2 and Figure 3b and 3c). Supplementary File 1: Supplementary File
186 Table S4 presents all model fits and DIC scores.

187 **[Figure 3 here]**

Figure 3. The relationship between human cysticercosis antibody (Ab)-seroprevalence and human age (in years) for each dataset. Ab-seroconversion (simple) or Ab-seroconversion with Ab-seroreversion (reversible) catalytic models (**a & b**) jointly fitted to multiple datasets (single diagnostic sensitivity and specificity values estimated; dataset-specific λ_{sero} and ρ_{sero} estimates obtained) and (**c**) models independently fitted to a single dataset, including 95% confidence intervals associated with observed Ab-seroprevalence point estimates. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the estimated parameter posterior distributions used to construct predicted (all age) seroprevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-fitting models were selected using the deviance information criterion (DIC); both models presented if difference between DIC < 2 (both models have similar support based on the data); a difference > 10 units indicates that the models are significantly different and therefore only superior fitting model (lowest DIC) is presented). The non-zero predicted seroprevalence at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CIs) for age-seroprevalence data-points are calculated by the Clopper-Pearson exact method.

Table 2. Antibody seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antibody) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).

Dataset	All-age observed sero- prevalence (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	λ_{sero} = seroconversion rate, year ⁻¹ (95% BCI)**	ρ_{sero} = seroreversion rate, year ⁻¹ (95% BCI)**
Models jointly fitted to multiple datasets (LLGP-EITB assay) ^a						
Lescano et al. 2009	24.66 (21.59 – 27.94)	Reversible ^b	0.976 (0.937 – 0.994)	0.980 (0.967 – 0.988)	0.12 (0.067 – 0.19)	0.38 (0.21 – 0.62)
Moro et al. 2003	20.82 (16.48 – 25.71)				0.11 (0.0504 – 0.21)	0.501 (0.23 – 0.92)
Jayaraman et al. 2011	15.81 (13.66 – 18.16)				0.019 (0.0095 – 0.093)	0.105 (0.042 – 0.56)
Theis et al. 1994	12.68 (10.48 – 15.16)				0.024 (0.011 – 0.052)	0.16 (0.054 – 0.38)
Gomes et al. 2002	1.64 (0.82 – 2.93)				0.000086 (0.000011 – 0.00066)	0.43 (0.098 – 1.49)
Models jointly fitted to multiple datasets (IgG Ab-ELISA) ^c						
Edia-Asuke et al. 2015	14.53 (10.72 – 19.06)	Simple ^b	0.872 (0.784 – 0.942)	0.974 (0.916 – 0.998)	0.0044 (0.0018 – 0.0064)	NA

Weka et al. 2013	9.60 (5.06 – 16.17)				0.0023 (0.00053 – 0.0046)	NA
Models independently fitted to an single dataset (rT24H-immunoblot) ^d						
Holt et al. 2016	2.96 (1.86 – 4.44)	Simple ^e	0.964 (0.914 – 0.988)	0.986 (0.969 – 0.997)	0.00044 (0.000049 – 0.00090)	NA

*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

**Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).

NA = Not applicable.

^aDiagnostic sensitivity and specificity jointly fitted for the LLGP-EITB assay (Tsang et al., 1989) across datasets.

^bBest-fitting model determined by DIC (models jointly fitted to multiple datasets).

^cDiagnostic sensitivity and specificity jointly fitted for the IgG Ab-ELISA (DiagnosticAutomation/CortezDiagnostic, Inc., 2016) across datasets.

^eBased on the rT24H-immunoblot (Hancock et al., 2006).

^dBest-fitting model determined by DIC (models independently fitted to a single dataset).

203

204 Global human cysticercosis (HCC) antigen seroprevalence

205 HCC infection acquisition with infection loss (reversible model) provided an improved fit for models
206 fitted jointly to multiple datasets based on B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al.,
207 2000) (Table 3 and Figure 4a), found in one hyperendemic setting (all-age HCC seroprevalence of
208 21.7%) in the DRC (Kanobana et al., 2011), and endemic settings in Zambia (Mwape et al., 2012),
209 Burkina Faso (Sahlu et al., 2019), Lao PDR (Conlan et al., 2012) and Cameroon (Ngeuekam et al.,
210 2003) (all-age HCC seroprevalences from 0.7% to 5.8%). For models fitted to the single dataset
211 from a hyperendemic setting in Kenya (6.61%) (Wardrop et al., 2015), using the HP10 Ag-ELISA
212 (Harrison et al., 1989), the (simple) model without infection loss provided an improved fit (Table 3

and Figure 4b). Supplementary File 1: Supplementary File Table S5 presents all model fits and DIC scores.

[Figure 4 here]

Figure 4. The relationship between human cysticercosis antigen (Ag)-seroprevalence and human age (in years) for each dataset. Infection acquisition (simple) or infection acquisition and loss (reversible) catalytic models (a) jointly fitted to multiple datasets (single diagnostic sensitivity and specificity values estimated; dataset-specific λ_{inf} and ρ_{inf} estimates obtained) and (b) models independently fitted to a single dataset, including 95% confidence intervals associated with observed Ag-seroprevalence point estimates. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the parameter posterior distributions used to construct predicted (all age) seroprevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-fitting model selected by deviance information criterion (DIC); both models presented if difference between DIC < 2 (both models have similar support based on the data); a difference > 10 units indicates that the models are significantly different and therefore only superior fitting model (lowest DIC) is presented). The non-zero predicted seroprevalence at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-seroprevalence data-points are calculated by the Clopper-Pearson exact method.

Table 3. Antigen seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antigen) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).

Dataset	All-age observed seroprevalen ce (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	λ_{inf} = infection acquisition rate, year ⁻¹ (95% BCI)**	ρ_{inf} = infection loss rate, year ⁻¹ (95% BCI)**
Models jointly fitted to multiple datasets (the B158/B60 Ag-ELISA) ^a						
Kanobana et al. 2011	21.66 (19.01 – 24.49)	Reversible ^b	0.909 (0.810 – 0.967)	0.999 (0.995 – 0.999)	0.11 (0.077 – 0.17)	0.330 (0.246 – 0.464)
Mwape et al. 2012	5.79 (4.19 – 7.77)				0.0044 (0.0027 – 0.0088)	0.023 (0.001 – 0.085)
Sahlu et al. 2019	2.45 (1.93 – 3.08)				0.0016 (0.00091 – 0.0032)	0.029 (0.0016 – 0.11)
Conlan et al. 2012	2.22 (1.49 – 3.17)				0.0018 (0.00073 – 0.0034)	0.063 (0.0076 – 0.12)
Nguekam et al. 2003	0.68 (0.47 – 0.95)				0.00017 (0.000077 – 0.00030)	0.004 (0.00018 – 0.026)
Models independently fitted to a single dataset (the HP10 Ag-ELISA) ^c						
Wardrop et al. 2015	6.61 (5.57 – 7.76)	Simple ^d	0.850 (0.735 – 0.927)	0.944 (0.930 – 0.959)	0.00054 (0.000053 – 0.0013)	NA

*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

****Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).**

NA = Not applicable.

^aDiagnostic sensitivity and specificity jointly fitted for the B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al., 2000).

^bBest-fitting model determined by DIC (models jointly fitted to multiple datasets).

^cBased on the HP10 Ag-ELISA (Harrison et al., 1989).

^dBest-fitting model determined by DIC (models independently fitted to a single dataset).

230

231

232 **Country-wide analysis of human cysticercosis antibody seroprevalence trends in Colombia**

233 HCC Ab-seroconversion with Ab-seroreversion (reversible model), fitted to multiple datasets using
234 an IgG Ab-ELISA (López et al. 1988), provided an improved fit across the 23 (out of a total of 24)
235 departments of Colombia (Flórez Sánchez et al., 2013) included in the analysis. Supplementary File
236 1: Supplementary Table S6 presents parameter estimates from the best-fit reversible model by
237 department (parameter estimates for the simple model fits by department can also be found in
238 Supplementary Table S7). Figure 5 presents the best-fit Ab-seroconversion with Ab-seroreversion
239 (reversible) model fit to each age-seroprevalence dataset across departments (Supplementary File
240 1: Supplementary Figure S3 zooms into model fits in medium to lower all-age seroprevalence
241 departments for improved resolution). One department (Bolívar) was omitted due to difficulty
242 fitting to such a distinct age-seroprevalence profile (prevalence peak in early ages).

243 Figure 6 highlights the geographical variation in a) HCC Ab-seroconversion or FoI, b) HCC Ab-
244 seroreversion rate and c) the HCC antibody all-age seroprevalence, across the 23 departments. In
245 addition, Figure 6 presents substantial geographical variation in risk factors, including: d) the
246 proportion of individuals owning pigs, and e) the proportion of individuals reporting open
247 defecation practices by department (Supplementary File 1: Supplementary Figure S4 highlights
248 variation in the proportion of pigs being kept under free-ranging management practices and the
249 proportion of pigs being kept under free-ranging/mixed practices in those owning pigs ($n=3,157$)).

[Figure 5 here]

Figure 5. The relationship between human cysticercosis antibody (Ab)-seroprevalence and human age (in years) for 23 departments in Colombia. Each graph shows observed human cysticercosis Ab age-seroprevalence data (black points) and fitted reversible model (Ab-seroconversion with Ab-seroreversion; best-fitting model). Y-axis units are from 0-1 (HCC Ab-seroprevalence), with major y-axis gridlines at 0, 0.2, 0.4, and 0.6 seroprevalence. X-axis units are from 0-80 years (human age), with major x-axis gridlines at 0, 20, 40, 60 and 80 years of age. *Note: Supplementary File 1: Supplementary Figure S7 zooms into predicted plots for a) medium all-age HCC Ab-seroprevalence (6.33–14.37% all-age seroprevalence) and b) low all-age HCC Ab-seroprevalence (0.48–4.92% all-age seroprevalence), to view more closely the age-seroprevalence trends and uncertainty around fitted seroprevalence.*

[Figure 6 here]

Figure 6. Geographic variation in, a) HCC antibody (Ab)-seroconversion rate (λ_{sero} or Fol), and b) HCC Ab-seroreversion rate (ρ_{sero}), c) human cysticercosis Ab all-age seroprevalence data, d) pig ownership proportion and e) open defecation reported proportion by department. The Fol (λ_{sero}) and Ab-seroreversion (ρ_{sero}) rates are parameter estimates obtained from the best-fit model with HCC Ab-seroconversion and Ab-seroreversion (reversible model). Note that San Andrés department is not clearly shown because of its size (small islands located in the top-left of a-c maps). For context, an all-age HCC Ab-seroprevalence = 0.126, HCC Ab-seroconversion rate (Fol or λ_{sero}) = 0.023 year⁻¹, and HCC Ab-seroreversion rate (ρ_{sero}) = 0.19 year⁻¹ was obtained in San Andrés

Force-of-infection across settings

A more intuitive approach to understanding the Fol (λ) is to consider its reciprocal, which here corresponds to the average time until humans become Ab-seropositive ($1/\lambda_{\text{sero}}$) or infected ($1/\lambda_{\text{inf}}$) as inferred through Ag-seropositivity. Equally, the reciprocal of ρ relates to the average duration that humans remain Ab-seropositive ($1/\rho_{\text{sero}}$) or infected ($1/\rho_{\text{inf}}$). Given the large number of

estimates obtained for HCC, parameter estimates from best-fit models were compared across settings (by all-age (sero)prevalence of each dataset and by country). Figure 7 shows an overall decline in the average time (in years) until humans become HCC Ab-seropositive or infected with increasing all-age HCC (sero)prevalence, noting 18 studies identified in endemic settings (0.48–5.71% all-age HCC (sero)prevalence), and 19 estimates in hyperendemic settings (6.33–38.68% all-age HCC seroprevalence). Within countries, there was significant variation in times until humans become HCC Ab-seropositive or infected (Supplementary File 1: Supplementary Figure S5a).

Figure 7b presents strong evidence for similar average durations of remaining Ab-seropositive ($1/p_{sero}$) across different endemicity settings and countries (Supplementary File 1: Supplementary Figure S5b). However, there was evidence for a trend of decreasing duration of humans remaining infected ($1/p_{inf}$) with increasing all-age prevalence (antigen-based studies; $n=5$).

[Figure 7 here]

Figure 7. The relationship between (a) the average time until humans become cysticercosis antibody (Ab)-seropositive or infected ($1/\lambda$) and overall (all-age) seroprevalence, and (b) the average time humans remain cysticercosis Ab seropositive or infected ($1/p$) and overall (all-age) seroprevalence. The plot is stratified by proposed endemicity levels defined as endemic ($>0\%$ and $<6\%$ all-age HCC seroprevalence), and hyperendemic ($\geq 6\%$ all-age HCC seroprevalence).

Discussion

This paper presents the first global FoI estimates for *T. solium* HTT and HCC, identifying geographical heterogeneity that supports calls to implement both locally-adapted control efforts (Johansen et al., 2017; Gabriël et al., 2017), and setting-specific parameterisations of *T. solium* transmission models to support such efforts (Dixon et al., 2019). We have also placed our HTT FoI estimates in the context of (putative) endemic or hyperendemic settings, with 0.44 per 1,000 people per year

for a (single) endemic setting, and from 9.6 to 21 per 1,000 per year for 2 hyperendemic settings. HCC FoI estimates ranged from 0.086 to 21 per 1,000 per year in (18, including Colombian departments) endemic settings (0.086–21 for Ab-based surveys; 0.17–4.4 for Ag-based surveys), and from 0.54–120 per 1,000 per year in (19) hyperendemic settings (2.3–120 for Ab-based surveys; 0.54–110 for Ag-based surveys). Further work will be required to refine the proposed (and preliminary) characterisation of endemicity levels, perhaps linked to severity/morbidity (as in other NTDs (Prost et al., 1979; Smith et al., 2013). This will be relevant to inform what constitutes a hyperendemic setting in need of intensified control interventions, as proposed in the WHO 2021–2030 goals for *T. solium* (World Health Organization, 2020). Our work also follows the 5 principles distilled by Behrend et al. (2020) for communicating policy-relevant NTD modelling to stakeholders and implementation partners (Supplementary File 1: Supplementary File Table S8).

Across epidemiological settings, there was a clear trend of decreasing average time until humans become HCC Ab-seropositive or infected as inferred through Ag-seropositivity (the reciprocal of λ_{sero} or λ_{inf}) with increasing all-age seroprevalence. This makes intuitive sense as the FoI increases in settings with more intense transmission (reflected by a higher all-age seroprevalence). It was not possible to discern whether such trends exist for HTT given the limited availability of HTT datasets with age-stratified prevalence data. Infection loss with infection acquisition was indicated for two HTT copro-Ag-ELISA-based surveys, and five of six HCC antigen-based surveys, supporting inclusion of parameters representing recovery from HTT and HCC in *T. solium* transmission models (Dixon et al., 2019). Our infection loss rates for HTT indicate that the duration of adult tapeworm infection (the reciprocal of ρ_{inf}) ranges from 1.3 to 1.4 years (with uncertainty bounds from 1.0 to 2.8 years), aligning with literature estimates suggesting that adult tapeworms live for less than 5 years (Garcia et al., 2014), although our values are only based on two studies. HCC Ab-seroreversion rates (or infection loss rates) from this analysis are also consistently larger than HCC Ab-seroconversion rates (or infection acquisition rates), in agreement with comparisons of HCC Ab-seroreversion to Ab-seroconversion (or Ag-seroreversion to Ag-seroconversion) estimates in the literature, which are

generally based on cumulative seroconversion and seroreversion proportions, or rule-based modelling approaches (Dermauw et al., 2018; Garcia et al., 2001; Coral-Almeida et al., 2015; Mwape et al., 2013).

Some of the modelled estimates presented here indicate large differences between FoI and Ab-seroreversion/infection loss rates. These differences are particularly evident in datasets, such as Brazil (Gomes et al., 2002) and Risaralda Department in Colombia (Flórez Sánchez et al., 2013), where the reversible model was selected for flat age-(sero)prevalence profiles in low (sero)prevalence settings, where the seroreversion parameter provided minimal information with large uncertainty. The flat age-(sero)prevalence in these settings may also be likely explained by false-positives generated given the slightly sub-optimal performance of the serological antibody diagnostic used (e.g. posterior median specificity estimates of 98% in Brazil (Gomes et al., 2002) for the antibody LLGP-EITB test (Tsang et al., 1989), highlighting issues with imperfect specificity of diagnostics in settings with very low transmission intensity.

The high cysticercosis Ab-seroreversion rates indicated across datasets are likely indicative of substantial transient responses generated from exposure without establishment of infection. This may also explain the high all-age Ab-seroprevalence estimates observed in field studies (Garcia et al., 2001). Even with Ag-based surveys, a marker of infection rather than exposure, Ag-positivity may still indicate some degree of transient responses due to partial establishment of (immature) cysts or establishment followed by rapid degeneration of (mature) cysts (Mwape et al., 2012). One expectation was that Ab-seroreversion and infection loss rates are fundamentally biological processes so would be fairly consistent across settings. Since Ab-seroreversion or infection loss parameters were allowed to vary among settings, the consistency of the posterior estimates for these parameters indicates that rates of HCC Ab-seroreversion are stable (i.e., no relationship between all-age Ab-seroprevalence and the average duration humans remain Ab-seropositive, Figure 7b; no relationship between the Ab-seroconversion and Ab-seroreversion rates,

Supplementary Figure S6), confirming this *a priori* expectation. The average duration humans remain infected (i.e., the reciprocal of the HCC infection loss rate), however, decreases with increasing seroprevalence (and a positive relationship between infection acquisition rates and infection loss rates, Supplementary Figure S6). Such a signal seen for Ag-based estimates, albeit with only 5 observations, may indicate increased transient responses in higher transmission settings due to more partial establishment of infection. There is however an absence of wider literature to support the hypothesis of exposure intensity affecting probability of successful parasite establishment, but such (transmission intensity-dependent) parasite establishment processes have been incorporated into transmission models for other NTDs (Hamley et al., 2019), highlighting an area of future research with implications for control efforts. In the case of Ab-seroreversion rates, where more data are available compared to infection loss rates, it may be suitable in future work to jointly fit the ρ_{sero} parameter for reversible models across settings.

This analysis also provides, for the first time, a detailed country-level analysis, focused on Colombia, exploring the geographical variation of key epidemiological metrics (Fol and antibody seroreversion) alongside understanding potential drivers of these trends, using a rich dataset generated by Flórez Sánchez and colleagues (2013). Our results identify substantial subnational variation in HCC Fol (measured by Ab-seroconversion) and Ab-seroreversion rates. There appears to be only a limited relationship between these epidemiological quantities, Ab-seroprevalence and other risk factors, including open defecation and pig ownership at the department level, highlighting the complex nature of exposure drivers for HCC. For example, the southeastern rural departments of Vaupés and Amazonas show the highest all-age seroprevalence and Fol estimates. But while Vaupés has one of the highest reported proportions of open defecation, pig ownership is low in both departments. Notwithstanding, substantial subnational variation indicates the need for tailored subnational approaches to control. Spatial variation has been explored formally for this dataset by including spatial structure (i.e., spatial correlation in seropositivity estimated up to approximately 140 km at the Municipality level) into a risk factor analysis, and identifying hot spots

of unexplained residual clustering in northern and southern municipalities in Colombia (Galipó et al., 2021). The findings from this study further supports the requirement for designing subnational and targeted interventions (risk groups such as those with low education levels and displaced persons), alongside the need to understand epidemiological dynamics at the subnational level.

A potential limitation of this study is the assumption that diagnostic sensitivity and specificity for a single diagnostic test do not vary substantially among settings (implied by estimating a single posterior for specificity and sensitivity using data from multiple surveys that used the same diagnostic). In reality, there may be some variation in diagnostic performance between settings, particularly for HTT serological diagnostics. For example, the widely used copro-Ag ELISA for detecting adult tapeworm infection is not species specific (Ng-Nguyen et al., 2017). Literature estimates indicate high specificity of HCC diagnostics; however, a proportion of positive results by both HCC Ag- and Ab- diagnostics may be due to transient responses and cross-reactions following exposure to the eggs of other other helminths including *Taenia saginata*, *Echinococcus granulosus* and *Schistosoma species* (Lightowers et al., 2016b; Noh et al., 2014; Kojic et al., 2003; Furrows et al., 2006). Limited information exists on the co-distribution and prevalence of potentially cross-reactive *Taenia* species (such as *Taenia saginata*) and other helminths to determine the relative contribution of within- and between-location variability in the performance of specific diagnostic tests.

The prevailing (and most parsimonious) assumption governing the behaviour of the catalytic models fitted in this analysis is of a constant FoI with respect to age. Collated age-(sero)prevalence profiles presented here largely reveal increasing (sero)prevalence with age, or saturation with age through Ab-seroreversion/infection loss, but this behaviour can also be observed with age-dependent infection rates (Grenfell and Anderson, 1985). However, the available data limit the testing of more complex FoI functions. A few datasets appeared indeed to deviate from the basic assumption, for example for HTT dynamics in the DRC (Madinga et al., 2017) and Bolívar in Colombia

(Flórez Sánchez et al., 2013). While it was not possible to fit the current formulation of catalytic models to these datasets, the specific age-prevalence peaks in younger ages may indicate other drivers such as heterogeneity in exposure (by age) or age-related immunity mechanisms. The observations of HTT copro-Ag-ELISA age-prevalence peaks/odds of infection in children from Peru, Guatemala and Zambia (Garcia et al., 2003a; Allan et al., 1996; Mwape et al., 2015) suggest that these trends might be more widespread. Age peaks in HTT prevalence could indicate the need for targeted mass drug administration (MDA) programmes, such as delivery of anthelmintics (praziquantel) to school-age children, an approach that could be integrated into existing schistosomiasis control programmes where HTT and schistosomiasis are co-endemic. Should more age-prevalence data become available, especially for HTT, fitting models with age-varying FoI may become relevant as indicated in other NTDs (Gambhir et al., 2009).

The results presented here, particularly for HCC, where many datasets were available, suggest marked geographical heterogeneity in FoI and associated all-age (sero)prevalence estimates. This indicates substantial variation in the intensity of *T. solium* transmission among endemic settings. There is strong evidence for both HCC Ab-seroreversion and infection loss, likely due to transient dynamics which highlights the need for careful interpretation of cross-sectional (sero)prevalence survey estimates. Catalytic models provide useful tools for interpreting such data, which are far more abundant than a few longitudinal surveys reported in the literature. We also quantify, for the first time, the presence of substantial subnational variation in exposure to HCC, highlighting the need for tailored, sub-national control strategies. More work is also required to understand whether age-prevalence peaks (as observed for HTT) are more commonplace, and whether age-targeted control strategies may be required under specific epidemiological and socioeconomic conditions.

Materials and methods

Identifying relevant literature, data sources and data extraction

Published articles with HTT and HCC age-(sero)prevalence or age-infection data suitable for constructing age-stratified profiles were identified through two routes. Firstly, by extracting eligible studies from a systematic review of *T. solium* HTT and HCC (sero)prevalence global ranges (Coral-Almeida et al. (2015)), and secondly, by updating the Coral-Almeida et al. (2015) review, using the same strategy (see Supplementary File 1: Supplementary Text S1), for the period 01/11/2014 to 02/10/2019.

Sub-national dataset for Colombia

Flórez Sánchez et al. (2013) conducted a country-level survey of HCC antibody seroprevalence across 24 of Colombia's 32 administrative departments, sampling 29,360 individuals. Permission was granted from *Instituto Nacional de Salud* to analyse these data to construct age-seroprevalence profiles. The study collected human cysticercosis Ab-seroprevalence data in the period 2008–2010, alongside risk-factor data using a three-stage clustered random sampling framework. To maintain suitable sample sizes for model fitting, age-seroprevalence profiles were constructed at the department level ($n = 850$ – $1,291$; Supplementary File 1: Supplementary Figure S7), rather than at municipality level ($n = 40$ – $1,140$). Age-seroprevalence profiles stratified by sex in each department revealed no clear differences (Supplementary File 1: Supplementary Figure S8a), therefore age-seroprevalence data were not stratified by sex for further analysis (but see Galipó et al., 2021). Due to difficulty fitting the specific catalytic models to data from the department of Bolívar, only 23 of 24 departments were assessed ($n = 28,100$).

Force-of-infection modelling for human taeniasis and human cysticercosis

The FoI, which describes the average (per capita) rate at which susceptible individuals seroconvert (become Ab-positive) or become infected, was estimated for HTT and HCC for each dataset. Simple

and reversible catalytic models (Figure 1), originally proposed for fitting to epidemiological data by Muench (1934), were fitted to HTT and HCC age-(sero)prevalence profiles. Model parameters fitted to Ab-datasets were interpreted as Ab-seroconversion (λ_{sero}) and Ab-seroreversion (ρ_{sero}) rates, while (copro-) Ag-datasets were interpreted as infection acquisition (λ_{inf}) and infection loss (ρ_{inf}) rates (Figure 1 provides further details of model structure and parameter interpretation). Like the Fol, the infection loss/ seroreversion parameter (ρ) was also permitted to vary across settings (Dermauw et al., 2018).

The true prevalence $p(a)$ at age a is given for the simple model by,

$$p(a) = 1 - e^{-\lambda(a)} \quad [1]$$

and for the reversible model by,

$$p(a) = \frac{\lambda}{\lambda + \rho} [1 - e^{-(\lambda + \rho)(a)}] \quad [2]$$

Model fitting and comparison

Analyses were performed in R version 4.0.5 (2021), following Dixon et al. (2020). A likelihood was constructed assuming that the observed data (representing a binary presence/absence of markers related to exposure or infection) are a realization of an underlying binomial distribution with probability $p(a)$, given by the catalytic model, and adjusted to give the observed prevalence, $p'(a)$, by the sensitivity (se) and specificity (sp) of the diagnostic adopted in the respective datasets (Diggle, 2011),

$$p'(a) = 1 - sp + se + sp - 1 \times p(a) \quad [3]$$

Therefore, the likelihood of the data on the number of observed Ab-seropositive or infected humans of age a , $r(a)$, from $n(a)$ humans is,

$$L(r, n | \theta) = \prod_a p'(a)^{r(a)} [1 - p'(a)]^{n(a) - r(a)} \quad [4]$$

where θ denotes, generically, the catalytic model (i.e. FoI, seroreversion/infection loss) and diagnostic performance (i.e., sensitivity and specificity) parameters. When the same diagnostic was used across surveys, sensitivity and specificity were assumed to be the same among surveys, yielding a single posterior distribution for the diagnostic performance (sensitivity, specificity) for each test (whilst retaining dataset-specific estimates of λ and p). The approach captures uncertainty in diagnostic sensitivity and specificity, but does not permit variation in performance across settings.

A Bayesian Markov chain Monte Carlo (MCMC) Metropolis–Hastings sampling algorithm was implemented to estimate the parameter posterior distribution $f(\theta|r, n)$, assuming uniform prior distributions for λ and p (Table 4). A weakly informative prior for λ , assuming a lognormal distribution (mean informed by the median estimate from the simple model fit, and a standard deviation of 1), was used for reversible model fits to prevent λ chains drifting to flat posterior space and failing to converge.

Informative beta distribution priors for the diagnostic sensitivity and specificity were defined to capture literature estimates of the mean and 95% CIs for these parameters; Supplementary File 1: Supplementary Table S1, Supplementary Figure S9 and S10 provide more detail).

A maximum of 20,000,000 iterations were run for models fitted simultaneously to multiple datasets (2,000,000 for models fitted to single datasets) to obtain a sufficient sample to reduce autocorrelation through substantial subsampling, with the first 25% of runs being discarded as burn-in. The parameter posterior distributions, used to generate fitted prevalence curves and associated uncertainties for each model fit, were summarised using the median and 95% Bayesian credible intervals (95% BCIs). Simple and reversible model fits were compared using the deviance information criterion (DIC) (Spiegelhalter et al., 2002), with the model producing the smallest DIC score being selected.

Table 4. Range for force-of-infection (Fol), λ , and seroreversion / infection loss, ρ , uniform priors.

<i>T. solium</i> indicator	λ : limits on uniform prior (year ⁻¹)	ρ : limits on uniform prior (year ⁻¹)	Rationale
HTT (copro-antigen (Ag) and antibody (Ab))	Minimum: 0 Maximum: 12	Minimum: 0.333 Maximum: 1	<p>λ: maximum seroconversion rate of 12 year⁻¹ = 1 month⁻¹ (1/λ), representing the lower limit before humans become copro-Ag positive (i.e., infected) or Ab-seropositive of 1 month</p> <p>ρ: minimum Ab-seroreversion or infection loss rate of 0.333 year⁻¹ = 0.0277 month⁻¹, or 36-month duration (1/ρ) for humans to remain copro-Ag (i.e., infected) or Ab-seropositive, reflecting the upper average limit assumed for the life-expectancy of adult <i>Taenia solium</i> of 3 years (Gonzalez et al., 2002); a maximum of 0.0833 month⁻¹ represents the minimum time humans remain copro-Ag (i.e., infected) or Ab-seropositive reflecting the minimum life-expectancy of the adult worm of 12 months (Garcia et al., 2003b) (1/ ρ)</p>
HCC (antigen and antibody)	Minimum: 0 Maximum: 12	Minimum: 0 Maximum: 12	Both λ and ρ : maximum infection acquisition/loss or Ab-seroconversion / Ab-seroreversion rate of 12 year ⁻¹ = 1 month ⁻¹ represents the lower limit before humans acquire infection or become Ab-seropositive (1/ λ), or remain HCC antigen (i.e., infected) or Ab-seropositivity (1/ ρ) of 1 month.
<p><i>N.B.</i> The reciprocal of the rates of λ and ρ give the duration of susceptibility (1/λ; 1/λ_{sero} for Ab-based, or 1/λ_{inf} for Ag-based) or of remaining infected or Ab-seropositive (1/ρ; 1/ρ_{sero} for Ab-based, or 1/ρ_{inf} for Ag-based). HTT: human taeniasis; Ab: antibody; Ag: antigen; HCC: human cysticercosis</p>			

495

496

497

Acknowledgements: NA

Competing interests:

All authors declare they do not have conflicts of interest.

Funding statement:

MAD, PW, CW, ZMC and MGB acknowledge funding from the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK MRC and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme supported by the European Union.

Data and code availability:

Code to replicate the analysis is provided at https://github.com/mrc-ide/human_tsol_FOI_modelling. All age-(sero)prevalence data are available in the following data repository: <http://doi.org/10.14469/hpc/10047>. Original data for two datasets available (under the [Creative Commons Attribution License; CC BY 4.0](#)) from the International Livestock Research Institute open-access repository (<http://data.ilri.org/portal/dataset/ecozd>) referenced in Holt et al. (2016) and University of Liverpool open-access repository (<http://datacat.liverpool.ac.uk/352/>) referenced in Fèvre et al. (2017).

References

- Allan JC, Ávila G, Garcia Noval J, Flisser A, Craig PS (1990) **Immunodiagnosis of taeniasis by coproantigen detection** *Parasitology* **101** Pt 3:473–7. doi: 10.1017/s0031182000060686
- Allan JC, Velasquez-Tohom M, Garcia-Noval J, Torres-Alvarez R, Yurrita P, Fletes C, Mata F de, Soto de Alfaro H, Craig PS (1996) **Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities** *Annals of Tropical Medicine and Parasitology* **90**(2):157–65. doi: 10.1080/00034983.1996.11813039
- Behrend MR, Basáñez MG, Hamley JID, Porco TC, Stolk WA, Walker M, de Vlas SJ; NTD Modelling Consortium (2020) **Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium** *PLoS Neglected Tropical Disease* **9**;14(4):e0008033. doi: 10.1371/journal.pntd.0008033.
- Braae, U.C., Gabriël, S., Trevisan, C. Thomas LF, Magnussen P, Abela-Ridder B, Ngowi H, Johansen MV (2019) **Stepwise approach for the control and eventual elimination of *Taenia solium* as a public health problem** *BMC Infectious Diseases* **19**:182. <https://doi.org/10.1186/s12879-019-3812-y>.
- Brandt JR, Geerts S, De Deken R, Kumar V, Ceulemans F, Brijs L, Falla N (1992) **A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in *Taenia saginata* cysticercosis** *International Journal of Parasitology* **22**:471–7. doi: 10.1016/0020-7519(92)90148-e
- Conlan J V, Vongxay K, Khamlome B, Dorny P, Sripa B, Elliot A, Blacksell SD, Fenwick S, Thompson RC (2012) **A cross-sectional study of *Taenia solium* in a multiple taeniid-endemic region reveals competition may be protective** *American Journal of Tropical Medicine and Hygiene* **87**:281–91. doi: 10.4269/ajtmh.2012.11-0106.
- Coral-Almeida M, Rodríguez-Hidalgo R, Celi-Erazo M, García HH, Rodríguez S, Devleeschauwer B, Benítez-Ortiz W, Dorny P, Praet N (2014) **Incidence of human *Taenia solium* larval infections in an Ecuadorian endemic area: implications for disease burden assessment and control** *PLoS Neglected Tropical Diseases* **8**: e2887. doi: 10.1371/journal.pntd.0002887

541 Coral-Almeida M, Gabriel S, Abatih EN, Praet N, Benitez W, Dorny P (2015) ***Taenia solium* Human**
542 **Cysticercosis: A Systematic Review of Sero-epidemiological Data from Endemic Zones around the**
543 **World** *PLoS Neglected Tropical Diseases* **9**:e0003919. doi: 10.1371/journal.pntd.0003919

544 CystiTeam Group for Epidemiology and Modelling of *Taenia solium* Taeniasis/Cysticercosis (2019) **The**
545 **World Health Organization 2030 goals for *Taenia solium*: Insights and perspectives from**
546 **transmission dynamics modelling: CystiTeam Group for Epidemiology and Modelling of *Taenia***
547 ***solium* Taeniasis/Cysticercosis** *Gates Open Research* **3**:1546. doi: 10.12688/gatesopenres.13068.2.

548 de Coster T, Van Damme I, Baauw J, Gabriël S (2018) **Recent advancements in the control of *Taenia***
549 ***solium*: A systematic review** *Food and Waterborne Parasitology* **13**:e00030. doi:
550 10.1016/j.fawpar.2018.e0003.

551 Dermauw V, Carabin H, Ganaba R, Cissé A, Tarnagda Z, Gabriël S, Dorny P, Millogo A (2018) **Factors**
552 **Associated with the 18-Month Cumulative Incidence of Seroconversion of Active Infection with**
553 ***Taenia solium* Cysticercosis: A Cohort Study among Residents of 60 Villages in Burkina** *American*
554 *Journal of Tropical Medicine and Hygiene* **99**(4):1018-1027. doi: 10.4269/ajtmh.18-0294.

555 DiagAutom. Human Cysticercosis IgG (*T. Solium*) ELISA Test kit. 2016. Available from:
556 <http://www.rapidtest.com/index.php?i=Parasitology-ELISA-kits&id=170&cat=17> [accessed 2020 Mar
557 9].

558 Diggle P (2011) **Estimating Prevalence Using an Imperfect Test** *Epidemiology Research International*.
559 doi: 10.1155/2011/608719

560 Dixon MA, Braae UC, Winskill P, Walker M, Devleesschauwer B, Gabriël S, Basáñez MG (2019)
561 **Strategies for tackling *Taenia solium* taeniosis/cysticercosis: A systematic review and comparison of**
562 **transmission models, including an assessment of the wider Taeniidae family transmission models**
563 *PLoS Neglected Tropical Diseases* **13**:e0007301. doi : 10.1371/journal.pntd.0007301.

564 Dixon MA, Winskill P, Harrison WE, Whittaker C, Schmidt V, Sarti E, Bawm S, Dione MM, Thomas LF,
565 Walker M, Basáñez MG (2020) **Force-of-infection of *Taenia solium* porcine cysticercosis: a modelling**
566 **analysis to assess global incidence and prevalence trends.** *Scientific Reports* **10**(1):17637. doi:
567 10.1038/s41598-020-74007-x.

568 Dixon MA, Winskill P, Harrison WE, Basáñez MG (2021) ***Taenia solium* taeniasis/cysticercosis: From**
569 **parasite biology and immunology to diagnosis and control** *Advances in Parasitology* **112**:133-217.
570 doi: 10.1016/bs.apar.2021.03.003.

571 Dorny P, Vercammen F, Brandt J, Vansteenkiste W, Berkvens D, Geerts S (2000) **Sero-epidemiological**
572 **study of *Taenia saginata* cysticercosis in Belgian cattle** *Veterinary Parasitology* **88**:43–9. doi:
573 10.1016/s0304-4017(99)00196-x

574 Edia-asuke AU, Inabo HI, Mukaratirwa S, Umoh VJ, Whong CMZ, Asuke S, Ella EE (2015)
575 **Seroprevalence of human cysticercosis and its associated risk factors among humans in areas of**
576 **Kaduna metropolis, Nigeria** *Journal Infectious Developing Countries* **9**:799–805. doi:
577 10.3855/jidc.5415

578 Flórez Sánchez AC, Pastrán SM, Vargas NS, Beltrán M, Enriquez Y, Peña AP, Villarreal A, Salamanca L,
579 Rincón E, Garzón IP, Muñoz L, Guasmayan L, Valencia C, Parra S, Hernandez N (2013) **Cisticercosis en**
580 **Colombia. Estudio de seroprevalencia 2008-2010** *Acta Neurológica Colombiana* **29**(2):73–86. ISSN
581 0120-8748.

582 Furrows SJ, McCroddan J, Bligh WJ, Chiodini P (2006) **Lack of specificity of a single positive 50-kDa**
583 **band in the electroimmunotransfer blot (EITB) assay for cysticercosis** *Clinical Microbiology and*
584 *Infection* **12**(5):459–62. doi: 10.1111/j.1469-0691.2006.01381.x

585 Gabriël S, Dorny P, Mwape KE, Trevisan C, Braae UC, Magnussen P, Thys S, Bulaya C, Phiri IK, Sikasunge
586 CS, Makungu C, Afonso S, Nicolau Q, Johansen MV (2017) **Control of *Taenia solium***

587 **taeniasis/cysticercosis: The best way forward for sub-Saharan Africa?** *Acta Tropica* **165**:252–60. doi:
588 10.1016/j.actatropica.2016.04.010.

589 Galipó E, Dixon MA, Fronterre C, Cucunubá ZM, Basáñez MG, Stevens K, Flórez Sánchez AC, Walker M
590 (2021) **Spatial distribution and risk factors for human cysticercosis in Colombia** *Parasites & Vectors*
591 **27**;14(1):590. doi: 10.1186/s13071-021-05092-8.

592 Gambhir M, Basáñez MG, Burton MJ, Solomon AW, Bailey RL, Holland MJ, Blake IM, Donnelly CA, Jabr
593 I, Mabey DC, Grassly NC (2009) **The development of an age-structured model for trachoma**
594 **transmission dynamics, pathogenesis and control** *PLoS Neglected Tropical Diseases* **3**:e462–e462.
595 doi: 10.1371/journal.pntd.0000462.

596 García HH, Gonzalez AE, Gilman RH, Palacios LG, Jimenez I, Rodriguez S, Verastegui M, Wilkins P, Tsang
597 VC; Cysticercosis Working Group in Peru (2001) **Short report: transient antibody response in *Taenia***
598 ***solium* infection in field conditions—a major contributor to high seroprevalence** *American Journal of*
599 *Tropical Medicine and Hygiene* **65**:31–32. doi: 10.4269/ajtmh.2001.65.31.

600 García H, Gilman R, Gonzalez A, Verastegui M, Rodriguez S, Gadivia C, Tsang VCW, Falcon N, Lescano
601 AG, Moulton LH, Bernal T, Tovar M, Cysticercosis Working Group in Perú (2003a) **Hyperendemic**
602 **Human and Porcine *Taenia Solium* Infection in Perú** *American Journal of Tropical Medicine and*
603 *Hygiene* **68**:268–75. PMID: 12685628.

604 García HH, Gonzalez AE, Evans CAW, Gilman RH, Cysticercosis Working Group in Perú (2003b) ***Taenia***
605 ***solium* cysticercosis** *Lancet* **362**:547–56. doi: 10.1016/S0140-6736(03)14117-7

606 García HH, Rodriguez S, Friedland JS Cysticercosis Working Group in Perú (2014) **Immunology of**
607 ***Taenia solium* taeniasis and human cysticercosis** *Parasite Immunology* **36**(8):388-96. doi:
608 10.1111/pim.12126.

609 Gomes I, Veiga M, Embiruçu EK, Rabelo R, Mota B, Meza-Lucas A, Tapia-Romero R, Carillo-Becerril BL,
610 Alcantara-Anguiano I, Correa D, Melo A (2002) **Taeniasis and cysticercosis prevalence in a small**

611 **village from Northeastern Brazil** *Arquivos de Neuro-Psiquiatria* **60**:93–103. doi: 10.1590/s0004-
612 282x2002000200006

613 Gonzalez AE, Gilman R, Garcia H, Lopez T (2002) **Use of a simulation model to evaluate control**
614 **programmes against *Taenia solium* cysticercosis** In: Singh G, Prabhakar S, editors. *Taenia solium*
615 *Cysticercosis From Basic to Clinical Science First*. London: CAB International. p. 437–48.

616 Grenfell BT, Anderson RM (1985) **The estimation of age-related rates of infection from case**
617 **notifications and serological data** *The Journal of Hygiene (London)* **95**(2):419-36. doi:
618 10.1017/s0022172400062859.

619 Gripper LB, Welburn SC (2017) **The causal relationship between neurocysticercosis infection and the**
620 **development of epilepsy—A systematic review** *Infect Disease of Poverty* **6**:31. doi: 10.1186/s40249-
621 017-0245-y.

622 Hamley JID, Milton P, Walker M, Basáñez MG (2019) **Modelling exposure heterogeneity and density**
623 **dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM:**
624 **Implications for elimination and data needs** *PLoS Neglected Tropical Diseases* **13**(12):e0007557.
625 doi:10.1371/journal.pntd.0007557

626 Hancock K, Pattabhi S, Whitfield FW, Yushak ML, Lane WS, Garcia HH, Gonzalez AE, Gilman RH, Tsang
627 VCW (2006) **Characterization and cloning of T24, a *Taenia solium* antigen diagnostic for cysticercosis**
628 *Molecular and Biochemical Parasitology* **147**:109–17. doi : 10.1016/j.molbiopara.2006.02.004

629 Harrison LJS, Joshua GWP, Wright SH, Parjhouse RME (1989) **Specific detection of circulating**
630 **surface/secreted glycoproteins of viable cysticerci in *Taenia saginata* cysticercosis** *Parasite*
631 *Immunology* **11**:351–70. doi:10.1111/j.1365-3024.1989.tb00673.x

632 Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, Praet N, Bellinger DC, de Silva NR,
633 Gargouri N, Speybroeck N, Cawthorne A, Mathers C, Stein C, Angulo FJ, Devleeschauwer B; World
634 Health Organization Foodborne Disease Burden Epidemiology Reference Group 2010 (2015) **World**

635 **Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne**
636 **Disease in 2010** *PLoS Medicine* 12(12):e1001923. doi: 10.1371/journal.pmed.1001923.

637 Holt HR, Inthavong P, Khamlome B, Blaszk K, Keokamphe C, Somoulay V, Phongmany A, Burr PA,
638 Graham K, Allen J, Donnelly B, Blacksell SD, Unger F, Grace D, Alonso S, Gilbert J (2016) **Endemicity of**
639 **Zoonotic Diseases in Pigs and Humans in Lowland and Upland Lao PDR: Identification of Socio-**
640 **cultural Risk Factors** *PLoS Neglected Tropical Diseases* 12:10(4):e0003913. doi:
641 10.1371/journal.pntd.0003913

642 Jayaraman T, Prabhakaran V, Babu P, Raghava MV, Rajshekhar V, Dorny P, Muliyl J, Oommen A (2011)
643 **Relative seroprevalence of cysticercus antigens and antibodies and antibodies to *Taenia ova* in a**
644 **population sample in south India suggests immunity against neurocysticercosis.** *Transactions of The*
645 *Royal Society of Tropical Medicine and Hygiene* 105:153–9. doi: 10.1016/j.trstmh.2010.10.007

646 Johansen MV, Trevisan C, Gabriël S, Magnussen P, Braae UC (2017) **Are we ready for *Taenia solium***
647 **cysticercosis elimination in sub-Saharan Africa?** *Parasitology* 144:59–64. doi:
648 10.1017/S0031182016000500.

649 Kanobana K, Praet N, Kabwe C, Dorny P, Lukanu P, Madinga J, Mitashi P, Verwijs M, Lutumba P, Olman
650 K (2011) **High prevalence of *Taenia solium* cysticercosis in a village community of Bas-Congo,**
651 **Democratic Republic of Congo** *International Journal Parasitology* 41:1015–8. doi:
652 10.1016/j.ijpara.2011.06.004.

653 Kojic EM, White AC Jr (2003) **A positive enzyme-linked immunoelectrotransfer blot assay result for a**
654 **patient without evidence of cysticercosis** *Clinical Infectious Diseases* 36(1):e7–9. doi:
655 10.1086/344445.

656 Lescano AG, Garcia HH, Gilman RH, Gavidia CM, Tsang VCW, Rodriguez S, Moulton LH, Villaran MV,
657 Montano SM, Gonzalez AE (2009) ***Taenia solium* Cysticercosis Hotspots Surrounding Tapeworm**

658 **Carriers: Clustering on Human Seroprevalence but Not on Seizures** *PLoS Neglected Tropical Diseases*
659 **3**(1):e371. doi: 10.1371/journal.pntd.0000371

660 Lightowlers MW, Donadeu M, Elaiyaraja M, Maithal K, Kumar KA, Gauci CG, Firestone SM, Sarasola P,
661 Rowan TG (2016a) **Anamnestic responses in pigs to the *Taenia solium* TSOL18 vaccine and**
662 **implications for control strategies** *Parasitology* **143**:416–20. doi: 10.1017/S0031182016000202

663 Lightowlers MW, Garcia HH, Gauci CG, Donadeu M, Abela-Ridder B (2016b) **Monitoring the outcomes**
664 **of interventions against *Taenia solium*: options and suggestions** *Parasite Immunology* **38**:158–69.
665 doi: 10.1111/pim.12291

666 López M, Murillo C, Sarria N, Nicholls R, Corredor A (1988) **Estandarización y evaluación de la prueba**
667 **de ELISA para la detección de anticuerpos en LCR y suero en neurocisticercosis** *Acta Neurológica*
668 *Colombiana* **4**:164–9.

669 Madinga J, Kanobana K, Lukanu P, Abatih E, Baloji S, Linsuke S Praet N, Kapinga S, Polman K, Lutumba
670 P, Speybroeck N, Dorny P, Harrison W, Gabriël S (2017) **Geospatial and age-related patterns of *Taenia***
671 ***solium* taeniasis in the rural health zone of Kimpese , Democratic Republic of Congo** *Acta Tropica*
672 **165**:100–9. doi:10.1016/j.actatropica.2016.03.013

673 Muench H (1943) **Derivation of Rates from Summation Data by the Catalytic Curve** *Journal of the*
674 *American Statistics Association* **29**:25–38. doi: 10.2307/2278457

675 Moro PL, Lopera L, Bonifacio N, Gilman RH, Silva B, Verastegui M, Gonzalez A, Garcia HH, Cabrera L,
676 Cysticercosis Working Group in Peru (2003) ***Taenia solium* infection in a rural community in the**
677 **Peruvian Andes** *Annals of Tropical Medicine and Parasitology* **97**:373–9.
678 doi:10.1179/000349803235002371

679 Mwape KE, Phiri IK, Praet N, Muma JB, Zulu G, van den Bossche P, de Deken R, Speybroeck N, Dorny
680 P, Gabriël S (2012) ***Taenia solium* infections in a rural area of Eastern Zambia-A community based**
681 **study** *PLoS Neglected Tropical Diseases* **6**(3):e1594. doi: 10.1371/journal.pntd.0001594

682 Mwape KE, Phiri IK, Praet N, Speybroeck N, Muma JB, Dorny P, Gabriël S (2013) **The incidence of**
683 **human cysticercosis in a rural community of eastern Zambia** *PLoS Neglected Tropical Diseases* **7**:
684 e2142.

685 Mwape KE, Phiri IK, Praet N, Dorny P, Muma JB, Zulu G, Speybroeck N, Gabriël S (2015) **Study and**
686 **Ranking of Determinants of *Taenia solium* Infections by Classification Tree Models** *American Journal*
687 *of Tropical Medicine and Hygiene* **92**:56–63. doi: 10.4269/ajtmh.13-0593.

688 Ng-Nguyen D, Stevenson MA, Dorny P, Gabriël S, Vo TV, Nguyen VT, Phan TV, Hii SF, Traub RJ (2017)
689 **Comparison of a new multiplex real-time PCR with the Kato Katz thick smear and copro-antigen**
690 **ELISA for the detection and differentiation of *Taenia* spp. in human stools** *PLoS Neglected Tropical*
691 *Diseases* **7**;11(7):e0005743.

692 Nguekam JP, Zoli AP, Zogo PO, Kamga ACT, Speybroeck N, Dorny P, Brandt J, Losson B, Geerts S (2003)
693 **A seroepidemiological study of human cysticercosis in West Cameroon** *Tropical Medicine and*
694 *International Health* **8**:144–9. doi: 10.1046/j.1365-3156.2003.01000.x.

695 Noh J, Rodriguez S, Lee Y-M, Handali S, Gonzalez AE, Gilman RH, Tsand VCW, Garcia HH, Wilkin PP
696 (2014) **Recombinant protein-and synthetic peptide-based immunoblot test for diagnosis of**
697 **neurocysticercosis** *Journal of Clinical Microbiology* **52**(5):1429–34. doi: 10.1128/JCM.03260-13

698 NTD Modelling Consortium Onchocerciasis Group (2019) **The World Health Organization 2030 goals**
699 **for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling**
700 **Consortium Onchocerciasis Group** *Gates Open Research* **26**;3:1545. doi:
701 10.12688/gatesopenres.13067.1.

702 Prost, A., Hervouet, J. P. & Thylefors, B (1979) **Les niveaux d'endémicité dans l'onchocercose** *Bulletin*
703 *of the World Health Organization* **57**, 655–662.

704 R Core Team (2021). **R: A language and environment for statistical computing**. R version 4.0.5. R
705 Foundation for Statistical Computing, Vienna, Austria. URL : <https://www.R-project.org/>.

706 Sahlu I, Carabin H, Ganaba R, Preux PM, Cisse AK, Tarnagda Z, Gabriël S, Dermauw V, Dorny P, Bauer
707 C, Milogo A (2019) **Estimating the association between being seropositive for cysticercosis and the**
708 **prevalence of epilepsy and severe chronic headaches in 60 villages of rural Burkina Faso** *PLoS*
709 *Neglected Tropical Diseases* **13**:e0007101. doi: 10.1371/journal.pntd.0007101

710 Smith JL, Flueckiger RM, Hooper PJ, Polack S, Cromwell EA, Palmer SL, Emerson PM, Mabey DCW,
711 Solomon AW, Haddad D, Brooker SJ (2013) **The geographical distribution and burden of trachoma in**
712 **Africa.** *PLoS Neglected Tropical Diseases* **7**: e2359. doi: 10.1371/journal.pntd.0002359.

713 Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) **Bayesian measures of model complexity**
714 **and fit** *Journal of the Royal Statistical Society Series B* **64**, 583–639. doi: 10.1111/1467-9868.00353

715 Theis JH, Goldsmith RS, Flisser A, Koss J, Chionino C, Plancarte A (1994) **Detection by immunoblot**
716 **assay of antibodies to *Taenia solium* cysticerci in sera from residents of rural communities and from**
717 **epileptic patients in Bali, Indonesia** *The Southeast Asian Journal of Tropical Medicine and Public*
718 *Health* **25**(3):464-8. PMID: 7777908.

719 Thomas LF, Cook EAJ, Fèvre EM, Rushton J (2019) **Control of *Taenia solium*; A Case for Public and**
720 **Private Sector Investment** *Frontiers in Veterinary Science* **6**:176. doi:10.3389/fvets.2019.00176

721 Tsang VC, Brand JA, Boyer AE (1989) **An enzyme-linked immunoelectrotransfer blot assay and**
722 **glycoprotein antigens for diagnosing human cysticercosis (*Taenia solium*)** *The Journal of Infectious*
723 *Diseases* **159**:50–9. doi: 10.1093/infdis/159.1.50

724 Wardrop NA, Thomas LF, Atkinson PM, de Glanville WA, Cook EAJ, Wamae CN, Gabriël S, Dorny P,
725 Harrison LJS, Fèvre EM (2015) **The Influence of Socio-economic, Behavioural and Environmental**
726 **Factors on *Taenia* spp. Transmission in Western Kenya: Evidence from a Cross-Sectional Survey in**
727 **Humans and Pigs** *PLoS Neglected Tropical Diseases* **7**:9(12):e0004223. doi:
728 10.1371/journal.pntd.0004223.

729 Weka RP, Ikeh EI, Kamani J (2013) **Seroprevalence of antibodies (IgG) to *Taenia solium* among pig**
730 **rearsers and associated risk factors in Jos metropolis, Nigeria** *The Journal of Infection in Developing*
731 *Countries* **15**:7(2):67-72. doi: 10.3855/jidc.2309

732 Welburn SC, Beange I, Ducrotoy MJ, Okello AL (2015) **The neglected zoonoses--the case for integrated**
733 **control and advocacy** *Clinical Microbiology and Infection* **21**(5):433-43. doi:
734 10.1016/j.cmi.2015.04.011.

735 Wilkins PP, Allan JC, Verastegui M, Acosta M, Eason AG, Garcia HH, Gonzalez AE, Gilman RH, Tsang VC
736 (1999) **Development of a serologic assay to detect *Taenia solium* taeniasis** *American Journal of*
737 *Tropical Medicine and Hygiene* **60**:199–204. doi: 10.4269/ajtmh.1999.60.199

738 World Health Organization, 2020 (2020). **Ending the Neglect to Attain the Sustainable Development**
739 **Goals: A Road Map for Neglected Tropical Diseases 2021–2030**. WHO, Geneva, Switzerland, pp. 63.
740 Available: https://www.who.int/neglected_diseases/WHONTD-roadmap-2030/en/.

741

Human taeniasis

a) Simple model (antibody seroconversion or infection acquisition only)

$$p(a) = 1 - e^{-\lambda(a)}$$

b) Reversible model (antibody seroconversion & seroreversion; or infection acquisition & loss)

$$p(a) = \frac{\lambda}{\lambda + \rho} \left[1 - e^{-(\lambda + \rho)(a)} \right]$$

Human cysticercosis

c) Simple model (antibody seroconversion; or infection acquisition only)

$$p(a) = 1 - e^{-\lambda(a)}$$

d) Reversible model (antibody seroconversion & seroreversion; or infection acquisition & loss)

$$p(a) = \frac{\lambda}{\lambda + \rho} \left[1 - e^{-(\lambda + \rho)(a)} \right]$$

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.22.22270710>; this version posted February 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Human taeniasis model parameters (a & b)		Human cysticercosis model parameters (c & d)	
	λ (year ⁻¹)	ρ (year ⁻¹)	
Antibody	Force of seroconversion (λ_{sero}): rate at which humans antibody seroconvert, which are raised in serum against <i>T. solium</i> adult tapeworm excretory-secretory (ES) products, indicative of active or past infection (Lightowlers et al., 2016a).	Rate of antibody seroreversion (ρ_{sero}).	Force of seroconversion (λ_{sero}): rate at which humans antibody seroconvert following exposure to <i>T. solium</i> infective stages (eggs via indirect environmental transmission) and/or infection with <i>T. solium</i> metacystode.
Antigen	Force of infection acquisition (λ_{inf}): rate at which humans develop an immature/mature adult tapeworm infection indicated by copro-antigen positivity.	Rate at which humans lose adult tapeworm infection indicated by becoming copro-antigen negative (ρ_{inf}).	Force of infection acquisition (λ_{inf}): rate at which humans acquire <i>T. solium</i> metacystode infection indicated by antigen positivity.
			Rate at which humans clear <i>T. solium</i> metacystode infection, indicating by becoming antigen negative (ρ_{inf}).

a **b**

a

b

c

a

Kanobana et al. (2011), DRC,
B158/B60 Ag-ELISA

Mwape et al. (2011), Zambia,
B158/B60 Ag-ELISA

Sahlu et al. (2019), Burkina Faso,
B158/B60 Ag-ELISA

Conlan et al. (2012), Lao PDR,
B158/B60 Ag-ELISA

Nguekam et al. (2003), Cameroon,
B158/B60 Ag-ELISA

Model fitted to data

Model with infection acquisition and loss

Age (years) of human host

b

Wardrop et al. (2014), Kenya,
HP10 Ag-ELISA

Model fitted to data Model with infection acquisition

Age (years) of human host

a

b

c

d

e

a **b**

Model selected • Reversible ▲ Simple **Diagnostic** — Antibody — Antigen